Research Analysts Offer Predictions for EW Q2 Earnings

Edwards Lifesciences Co. (NYSE:EW - Free Report) - Equities research analysts at William Blair increased their Q2 2026 earnings per share (EPS) estimates for Edwards Lifesciences in a research report issued to clients and investors on Thursday, April 24th. William Blair analyst M. Andrew now forecasts that the medical research company will earn $0.69 per share for the quarter, up from their prior forecast of $0.68. The consensus estimate for Edwards Lifesciences' current full-year earnings is $2.45 per share. William Blair also issued estimates for Edwards Lifesciences' Q3 2026 earnings at $0.69 EPS and Q4 2026 earnings at $0.70 EPS.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.60 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The company had revenue of $1.41 billion during the quarter, compared to analysts' expectations of $1.40 billion. During the same period in the prior year, the business earned $0.66 EPS.

Several other analysts have also recently weighed in on the stock. Stifel Nicolaus raised shares of Edwards Lifesciences from a "hold" rating to a "buy" rating and increased their price target for the company from $75.00 to $90.00 in a research note on Thursday, January 30th. Canaccord Genuity Group raised their target price on Edwards Lifesciences from $68.00 to $71.00 and gave the stock a "hold" rating in a research note on Thursday, February 13th. Morgan Stanley lifted their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a research report on Wednesday, February 12th. Truist Financial lowered their price target on Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating for the company in a report on Friday, April 11th. Finally, Robert W. Baird upped their target price on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the company a "neutral" rating in a research report on Thursday. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $79.25.

Edwards Lifesciences Trading Up 6.7 %

Shares of EW opened at $75.15 on Friday. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The firm has a 50-day moving average price of $70.93 and a 200 day moving average price of $71.02. Edwards Lifesciences has a 12-month low of $58.93 and a 12-month high of $95.25. The firm has a market capitalization of $44.18 billion, a P/E ratio of 10.78, a P/E/G ratio of 4.82 and a beta of 1.15.

Institutional Trading of Edwards Lifesciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Crowley Wealth Management Inc. acquired a new stake in Edwards Lifesciences during the 4th quarter worth $26,000. Vega Investment Solutions acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth about $27,000. Millstone Evans Group LLC purchased a new stake in shares of Edwards Lifesciences in the 4th quarter valued at about $29,000. Global X Japan Co. Ltd. boosted its position in shares of Edwards Lifesciences by 116.1% in the 1st quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock valued at $29,000 after purchasing an additional 216 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. purchased a new position in Edwards Lifesciences during the 4th quarter worth approximately $30,000. Institutional investors and hedge funds own 79.46% of the company's stock.

Insider Buying and Selling

In related news, VP Donald E. Bobo, Jr. sold 9,500 shares of the stock in a transaction on Monday, April 14th. The stock was sold at an average price of $69.81, for a total value of $663,195.00. Following the transaction, the vice president now owns 47,206 shares of the company's stock, valued at $3,295,450.86. This represents a 16.75 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $75.76, for a total value of $852,300.00. Following the sale, the chief financial officer now directly owns 30,561 shares of the company's stock, valued at $2,315,301.36. This trade represents a 26.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 71,853 shares of company stock worth $5,163,062. Company insiders own 0.34% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.